Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
ROSG [NASD]
Rosetta Genomics, Ltd.
Index- P/E- EPS (ttm)-21.86 Insider Own- Shs Outstand10.48M Perf Week-10.59%
Market Cap39.82M Forward P/E- EPS next Y-1.05 Insider Trans- Shs Float10.44M Perf Month-40.99%
Income-26.40M PEG- EPS next Q- Inst Own1.50% Short Float7.41% Perf Quarter6.44%
Sales0.50M P/S79.65 EPS this Y83.50% Inst Trans- Short Ratio1.53 Perf Half Y19.50%
Book/sh3.03 P/B1.25 EPS next Y22.80% ROA-140.50% Target Price3.50 Perf Year14.46%
Cash/sh2.76 P/C1.38 EPS next 5Y- ROE-170.40% 52W Range2.35 - 6.69 Perf YTD30.14%
Dividend- P/FCF5.69 EPS past 5Y50.30% ROI-26.90% 52W High-43.20% Beta-2.77
Dividend %- Quick Ratio14.80 Sales past 5Y- Gross Margin- 52W Low61.70% ATR0.42
Employees45 Current Ratio14.80 Sales Q/Q- Oper. Margin- RSI (14)33.59 Volatility8.46% 9.46%
OptionableYes Debt/Eq0.00 EPS Q/Q94.00% Profit Margin- Rel Volume0.28 Prev Close3.81
ShortableYes LT Debt/Eq0.00 EarningsMar 31 AMC Payout- Avg Volume507.60K Price3.80
Recom2.70 SMA20-21.88% SMA50-19.85% SMA2006.41% Volume141,383 Change-0.26%
30-Oct-13Downgrade Aegis Capital Buy → Hold $10 → $3.50
05-Apr-14 01:04PM  ROSETTA GENOMICS LTD. Financials EDGAR Online Financials
04-Apr-14 08:15AM  Rosetta Genomics to Receive U.S. Patent for Cancer Origin Assay Marketwired
02-Apr-14 09:08AM  Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly Develop microRNA-Based Diagnostics and Therapeutics for Rare Diseases Marketwired
08:00AM  ROSG: Three Platforms Will Drive Revenue Growth in 2014 and Beyond Zacks Small Cap Research
01-Apr-14 10:00AM  Full Year 2013 Rosetta Genomics Ltd Earnings Call scheduled for 10:00 am ET today CCBN
07:34AM  Full Year 2013 Rosetta Genomics Ltd Earnings Call scheduled for 10:00 am ET today CCBN
12:17AM  Full Year 2013 Rosetta Genomics Ltd Earnings Call scheduled for 10:00 am ET today CCBN
31-Mar-14 06:05PM  Rosetta Genomics Reports 2013 Financial Results Marketwired
03:17PM  Notable companies reporting after market close at theflyonthewall.com
07:07AM  Full Year 2013 Rosetta Genomics Ltd Earnings Release - After Market Close CCBN
25-Mar-14 02:50PM  Rosetta Genomics to Host Business Update Conference Call on April 1, 2014 Marketwired -5.41%
24-Mar-14 09:15AM  Rosetta Genomics Enters Collaboration With Clalit Health Services' Rabin Medical Center for microRNA-Based Assay for Chronic Allograft Dysfunction Following Kidney Transplantation Marketwired
21-Mar-14 12:15PM  Rosetta Genomics' Cancer Origin Test Highlighted at Landmark CUP Foundation Seminar 2014 Marketwired -9.47%
12-Mar-14 11:00AM  Rosetta Genomics: Pipeline Provides Sustainable Growth Zacks Small Cap Research
11:00AM  Rosetta Genomics: Pipeline Provides Sustainable Growth
08:15AM  Rosetta Genomics Provides Product Pipeline Update Marketwired
08:15AM  Rosetta Genomics Provides Product Pipeline Update
07-Mar-14 08:21AM  Rosetta Genomics: The Leader In MicroRNA-Based Molecular Diagnostics at Seeking Alpha
08:21AM  Rosetta Genomics: The Leader In MicroRNA-Based Molecular Diagnostics
06-Mar-14 08:10AM  Rosetta Genomics (ROSG) - Initiating with an Outperform Zacks Small Cap Research +6.59%
03-Mar-14 09:15AM  Rosetta Genomics Announces Publication of Data Correlating miR-150 to Atrial Fibrillation in Patients With Chronic Systolic Heart Failure Marketwired
09:15AM  Rosetta Genomics Announces Publication of Data Correlating miR-150 to Atrial Fibrillation in Patients With Chronic Systolic Heart Failure
26-Feb-14 08:45AM  Rosetta Genomics to Receive Important U.S. Patent for Oncology Therapeutic Marketwired
08:45AM  Rosetta Genomics to Receive Important U.S. Patent for Oncology Therapeutic
18-Feb-14 08:45AM  Rosetta Genomics Executes Agreement With MultiPlan Marketwired
08:45AM  Rosetta Genomics Executes Agreement With MultiPlan
08:25AM  Rosetta Genomics Appoints Kevin Watson as Director, Reimbursement-Managed Care Marketwired
08:25AM  Rosetta Genomics Appoints Kevin Watson as Director, Reimbursement-Managed Care
21-Jan-14 08:30AM  Rosetta Cancer Origin Test Now Covered by Highmark Health Services, the Fourth Largest U.S. Blue Cross and Blue Shield-Affiliated Company Marketwired +8.19%
08:30AM  Rosetta Cancer Origin Test Now Covered by Highmark Health Services, the Fourth Largest U.S. Blue Cross and Blue Shield-Affiliated Company Marketwire
08:30AM  Rosetta Cancer Origin Test Now Covered by Highmark Health Services, the Fourth Largest U.S. Blue Cross and Blue Shield-Affiliated Company
16-Jan-14 07:59AM  Rosetta Genomics platform predicts bladder cancer progression in published study at theflyonthewall.com
07:59AM  Rosetta Genomics platform predicts bladder cancer progression in published study
07:54AM  Rosetta Genomics' Platform Predicts Bladder Cancer Progression in Study Published in Urologic Oncology: Seminars and Original Investigations Marketwired
07:54AM  Rosetta Genomics' Platform Predicts Bladder Cancer Progression in Study Published in Urologic Oncology: Seminars and Original Investigations Marketwire
07:54AM  Rosetta Genomics' Platform Predicts Bladder Cancer Progression in Study Published in Urologic Oncology: Seminars and Original Investigations
13-Jan-14 08:00AM  Rosetta Genomics Announces Master Service Provider Agreement With a Major, Global Biopharmaceutical Company Marketwired +18.18%
08:00AM  Rosetta Genomics Announces Master Service Provider Agreement With a Major, Global Biopharmaceutical Company Marketwire
08:00AM  Rosetta Genomics Announces Master Service Provider Agreement With a Major, Global Biopharmaceutical Company
11-Dec-13 10:29AM  Recapping Recent Events In Rosetta Genomics - 2014 Could Be A Breakout Year at Seeking Alpha +5.32%
10:29AM  Recapping Recent Events In Rosetta Genomics - 2014 Could Be A Breakout Year
10-Dec-13 09:00AM  Rosetta Collaborative Study Profiling microRNAs Published in Clinical & Translational Oncology Marketwired
09:00AM  Rosetta Collaborative Study Profiling microRNAs Published in Clinical & Translational Oncology Marketwire
09:00AM  Rosetta Collaborative Study Profiling microRNAs Published in Clinical & Translational Oncology
09-Dec-13 08:30AM  Rosetta Genomics Announces New York State Approval for the Rosetta Kidney Cancer Test(TM) Marketwired
08:30AM  Rosetta Genomics Announces New York State Approval for the Rosetta Kidney Cancer Test(TM) Marketwire
08:30AM  Rosetta Genomics Announces New York State Approval for the Rosetta Kidney Cancer Test(TM)
02-Dec-13 09:02AM  InPlay: Rosetta Genomics issues letter to shareholders; says 'November was by far the strongest month for our Cancer Origin Test... we estimate our gross billings will pass the $1 million dollar mark by year-end' Briefing.com
09:00AM  Rosetta Genomics Issues Letter to Shareholders Marketwired
09:00AM  Rosetta Genomics Issues Letter to Shareholders Marketwire
09:00AM  Rosetta Genomics Issues Letter to Shareholders
27-Nov-13 09:10AM  Rosetta Genomics to Participate in the LD Micro Conference Marketwired
09:10AM  Rosetta Genomics to Participate in the LD Micro Conference Marketwire
09:10AM  Rosetta Genomics to Participate in the LD Micro Conference
20-Nov-13 08:30AM  Rosetta Genomics Expands microRNA Cancer Testing Services Agreement With GeneKor to Include Turkey and Romania Marketwired
08:30AM  Rosetta Genomics Expands microRNA Cancer Testing Services Agreement With GeneKor to Include Turkey and Romania Marketwire
08:30AM  Rosetta Genomics Expands microRNA Cancer Testing Services Agreement With GeneKor to Include Turkey and Romania
07-Nov-13 09:12AM  InPlay: Rosetta Genomics granted U.S. patent allowance for the use of microRNAs to treat liver cancer Briefing.com
09:06AM  Rosetta Genomics Granted U.S. Patent Allowance for the Use of microRNAs to Treat Liver Cancer Marketwired
09:06AM  Rosetta Genomics Granted U.S. Patent Allowance for the Use of microRNAs to Treat Liver Cancer
06-Nov-13 08:30AM  InPlay: Rosetta Genomics reports first payment from the UK's national health service for the Rosetta cancer origin test Briefing.com
08:30AM  Rosetta Genomics Reports First Payment From the UK's National Health Service for the Rosetta Cancer Origin Test(TM) Marketwired
08:30AM  Rosetta Genomics Reports First Payment From the UK's National Health Service for the Rosetta Cancer Origin Test(TM)
31-Oct-13 08:53AM  Rosetta Genomics announces sponsored research agreement with Ramot at TAU at theflyonthewall.com
08:53AM  Rosetta Genomics announces sponsored research agreement with Ramot at TAU
08:30AM  Rosetta Genomics Announces Sponsored Research Agreement With Ramot at Tel Aviv University Marketwired
08:30AM  Rosetta Genomics Announces Sponsored Research Agreement With Ramot at Tel Aviv University
30-Oct-13 10:03AM  Rosetta Genomics downgraded by Aegis Capital Briefing.com -12.90%
02:03AM  Rosetta Genomics downgraded by Aegis Capital Briefing.com
22-Oct-13 09:44AM  Rosetta Genomics receives USPTO patent for lung cancer test at theflyonthewall.com
18-Oct-13 12:51PM  St. Jude Medical Founder to Deliver Keynote Presentation at RedChip Emerging Growth Showcase GlobeNewswire
17-Oct-13 08:32AM  InPlay: Rosetta Genomics presents data supporting use of co's cancer origin test for familial cancer risk assessment and genetic counseling at ASHG meeting Briefing.com
08:30AM  Rosetta Genomics' Announces Poster Presentation at the American Society of Human Genetics Annual Meeting 2013 Marketwired
16-Oct-13 08:35AM  Rosetta Genomics cancer origin test incorporated into Altos Solutions' OncoEMR theflyonthewall.com
08:30AM  Rosetta Genomics' Cancer Origin Test Incorporated Into Altos Solutions' OncoEMR(R) Software Electronic Medical Record Marketwired
25-Sep-13 10:37AM  Rosetta Genomics to Participate at the Aegis Capital 2013 Healthcare Conference Marketwired
23-Sep-13 09:02AM  Rosetta Genomics' Cancer Origin Test Highlighted on The Dr. Steve Show Marketwired
12-Sep-13 08:31AM  InPlay: Rosetta Genomics granted US patent allowance; covers methods of use and composition of matter for diagnosing risk and treatment planning for preeclampsia Briefing.com
08:30AM  Rosetta Genomics Granted U.S. Patent Allowance Marketwired
10-Sep-13 10:00AM  The Coca-Cola Company Earnings Call scheduled for 10:00 am ET today CCBN
10:00AM  Rosetta Genomics Business Update Call scheduled for 10:00 am ET today CCBN
08:00AM  Rosetta Genomics Reports Financial Results for the First Six Months of 2013 Marketwired
09-Sep-13 08:30AM  Rosetta Genomics Executes Credentialing Agreements With Two National Healthcare Preferred Provider Networks Marketwired +8.54%
07:07AM  Q2 2013 Rosetta Genomics Ltd. Earnings Release - After Market Close CCBN
04-Sep-13 08:00AM  Rosetta Genomics to Host Business Update Conference Call on September 10, 2013 Marketwired
08-Aug-13 09:38AM  Rosetta Genomics and Ramot at Tel Aviv University Awarded Grant From Israeli Office of the Chief Scientist to Support Development of microRNA Oncology Therapeutics Marketwired
05-Aug-13 08:30AM  Rosetta Genomics Announces Launch of New Website Marketwired
25-Jul-13 09:05AM  Rosetta Genomics Receives Notice of Allowance for Key U.S. Patent for the Rosetta Lung Cancer Test Accesswire
13-Jun-13 12:31PM  InPlay: Rosetta Genomics: Medicare Administrator issues final local coverage determination for Rosetta cancer origin test Briefing.com +7.33%
12:30PM  Medicare Administrator Issues Final Local Coverage Determination for Rosetta Cancer Origin Test PR Newswire
07-Jun-13 06:49PM  4 Healthcare Stock Stories As a Weekend Investment Prescription at Wall St. Cheat Sheet +6.17%
12:46PM  Wal-Mart Okays Share Buyback, AT&T and Sprint Included in NSA Sweep, and 2 More Hot Stocks at Wall St. Cheat Sheet
08:44AM  Rosetta Genomics executes credentialing agreement with Three Rivers at theflyonthewall.com
08:30AM  Rosetta Genomics Executes Credentialing Agreement with Three Rivers Provider Network PR Newswire
06-Jun-13 06:40PM  4 Healthcare Stock Stories Creating a Thursday Buzz at Wall St. Cheat Sheet
02:25PM  5 Stocks Under $10 Set to Soar at TheStreet
08:33AM  InPlay: Rosetta Genomics announced acceptance for publication by molecular cancer of rosetta cancer origin test manuscript; fifth validation study demonstrating ability to identify tumor origin in patients with cancer of unknown or uncertai Briefing.com
08:30AM  Rosetta Genomics Announces Acceptance for Publication by Molecular Cancer of Rosetta Cancer Origin Test Manuscript PR Newswire
04-Jun-13 02:06PM  3 Health Care Stocks Under $10 to Watch at TheStreet +8.22%
08:35AM  Rosetta Genomics expands in U.S. theflyonthewall.com
Rosetta Genomics Ltd. develops and commercializes microRNAs based diagnostic tests and therapeutics. MicroRNAs are a group of genes that are produced using instructions encoded in DNA. It offers diagnostic tests, including Rosetta Cancer Origin test, a microRNA-based diagnostic to identify 42 tumor types that include carcinomas, soft tissue tumors, lymphoma, and other malignancies; Rosetta Mesothelioma test to differentiate mesothelioma, a cancer connected to asbestos exposure and other risk factors, from other carcinomas in the lung and pleura; Rosetta Lung Cancer test, a lung cancer classification test for cytology samples; and Rosetta Kidney Cancer test, a microRNA-based kidney tumor classification test for pathology samples. The company also focuses on developing tissue-based microRNA biomarkers for the differential diagnosis of indeterminate thyroid fine needle aspirate samples; blood-based microRNA biomarkers in order to develop a new diagnostic test for early diagnosis and refined risk stratification of patients following myocardial infarction; microRNA-based diagnostic test for the early diagnosis of Alzheimer's disease; and blood- or urine-based microRNA biomarkers to develop a diagnostic test for chronic kidney rejection. It distributes its products primarily in Australia, Canada, Greece, India, Israel, New Zealand, Qatar, Romania, Saudi Arabia, Singapore, Turkey, and the United Arab Emirates. The company has a collaboration agreement with Clalit Health Services for the development of a non-invasive microRNA-based assay for the diagnosis of chronic allograft dysfunction or chronic rejection, following kidney transplantation; and a strategic alliance with Marina Biotech, Inc. to develop microRNA-based diagnostics and therapeutics for rare diseases. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.